After 'confusion' over Trump team's directives, critical NIH research will continue for now
Read Original Source
Despite concerns about the future of research at the National Institutes of Health, current clinical trials can continue as scheduled, the agency’s acting director told staff scientists in an email Monday. Limited time: Save 25% on NBC News subscription Get exclusive reporting, live Q&As and ad-free reading. The clarification followed what staffers called “chaos” Wednesday when the Trump administration “paused” all communications from federal health agencies and suspended all government travel.
AI Summary
Main Idea: NIH acting director Dr. Matthew Memoli said critical clinical trials can continue for now, even as new research funding stays on hold after confusion over Trump administration directives.
Key Points:
- Memoli told staff that clinical trials at NIH and NIH-funded sites are still allowed to keep going.
- Patients can still take part in NIH trials, and researchers can keep paying for supplies and travel tied to treatment.
- The pause has left new grants and project funding in limbo, which could delay research on diseases like cancer, asthma, Covid, and Ebola.
- Memoli said more guidance is expected from the Department of Health and Human Services this week.
Impact on the People
Negative Impact
New NIH grant delays can slow research on cancer, asthma, and infectious disease, and patients may wait longer for new treatments.
Positive Impact
Current NIH clinical trials can keep going, so some patients can stay in care and research jobs and travel support are less disrupted.
How did each entity affect people?
Rate how each entity in this article affected the American people.
- Primary:
- Major:Department of Health and Human Servicesgovernment agency or body
Candidate Entities7 candidates · 5 weighted vote min · 70% decision
- Director Dr. Matthew MemolipersonPrimaryEvaluated
Central NIH official whose email clarified that clinical trials can continue and who is the key decision-making voice.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Department of Health and Human Servicesgovernment agency or bodyMajorEvaluated
Expected to issue additional guidance that will shape NIH operations and the scope of the pause.
Include 0 (0%)Ignore 0 (0%)5 to threshold - National Institutes of Healthgovernment agency or bodyPrimaryAI selected
Main institution affected by the pause, continued research, and new funding hold described in the article.
Include 0 (0%)Ignore 0 (0%)5 to threshold - President Donald TrumppersonMajorAI selected
His administration’s directives triggered the confusion and pause affecting NIH communications and travel.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Dr. Jay BhattacharyapersonContextCandidate
Named nominee for NIH director whose confirmation status is part of the article’s context.
Include 0 (0%)Ignore 0 (0%)5 to threshold - NIH Clinical Centereducational / research institutionContextCandidate
Specific NIH facility where clinical trials and patient care are said to continue.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Stanford Universityeducational / research institutionMinorCandidate
Bhattacharya’s institutional affiliation is mentioned as background on a central named figure.
Include 0 (0%)Ignore 0 (0%)5 to threshold
Comments 0
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment